Augmentin SJS Cases in California: How to Prove Causation

What SJS/TEN Is and Why Causation Is Often the Hardest Part

SJS and TEN are severe mucocutaneous reactions that can include blistering, epidermal detachment, mucous membrane injury, ocular complications, and prolonged disability. Clinically, SJS/TEN is widely recognized as rare and serious, and it can be associated with medications as well as other triggers. Because multiple plausible causes may be in play, the dispute in an Augmentin case often centers on whether the medication was a legally significant cause rather than a coincidental exposure. For background medical overviews, see DermNet’s SJS/TEN summary.

The Two Levels of Causation: General vs. Specific

In many prescription drug cases, causation is discussed in two steps:

• General causation: Can Augmentin (amoxicillin/clavulanate) cause SJS/TEN in humans?
• Specific causation: Did Augmentin cause this patient’s SJS/TEN under the facts of the case?

General causation is often built from medical literature, pharmacovigilance, and labeling history. Specific causation is usually built from the patient’s chronology, clinical course, and a documented rule-in/rule-out analysis by qualified experts.

General Causation: Evidence Commonly Used in Augmentin–SJS Allegations

General causation is typically supported with multiple lines of evidence rather than a single definitive item. Common categories include:

• Regulatory/labeling evidence: Whether severe cutaneous adverse reactions (including SJS/TEN) are described in approved labeling. See the FDA’s Drugs@FDA label repository (search “Augmentin”).
• Case reports/series: These can help demonstrate temporal patterns and clinical plausibility, while also having known limitations for quantifying risk.
• Pharmacovigilance data: Post-marketing reports can help identify a signal, but databases like FAERS have limitations (for example, underreporting, duplicates, reporting bias, and no reliable denominator). See the FDA’s FAERS dashboard information and limitations.
• Mechanism/immunology: SJS/TEN is generally described as an immune-mediated adverse drug reaction, and mechanistic plausibility may support (but usually does not replace) clinical and epidemiologic evidence.

Specific Causation: Building the Case Around the Patient’s Timeline

Specific causation often rises or falls on chronology and documentation. Key points often include:

• Why it was prescribed: The underlying infection (or suspected infection) may be argued as a competing explanation.
• Start date, dose, and actual ingestion: Prescribing notes, pharmacy dispensing records, and patient history often matter.
• Onset of prodrome: Fever, sore throat, malaise, and eye irritation can precede skin findings in SJS/TEN.
• Rash onset and progression: First documented rash, mucosal involvement, and speed of progression are often central.
• Stop date (dechallenge): Whether the drug was discontinued when symptoms appeared and what happened afterward (progression after stopping can still occur in immune-mediated reactions).
• Other exposures: Other prescriptions, OTC drugs, supplements, and inpatient-administered medications may complicate attribution.
• Hospital course: Dermatology/ophthalmology consultations, biopsy/pathology (if performed), and discharge diagnoses.

Differential Etiology: A Common Method for Specific Causation

Defense teams frequently argue that SJS/TEN can have multiple possible triggers, or that an alternative cause is more likely. In response, causation experts often use differential etiology (a clinical rule in/rule out approach) to explain why Augmentin is the most likely cause on this record. This commonly involves:

• Ruling in plausible causes: Recent new drugs, known higher-risk medication classes, and relevant infections.
• Ruling out alternatives: Using timing, exposure history, labs, and clinical features to explain why an alternative is less consistent with the presentation.
• Addressing multi-drug exposure: Relative timing, known association strength in the literature, and sequence of discontinuation.

In California, expert opinions must be based on matter of a type that reasonably may be relied upon and must reflect a reliable basis; courts act as gatekeepers for speculative expert opinions. See Sargon Enterprises, Inc. v. University of Southern California and California Evidence Code section 801.

Key Medical Records and Documents That Tend to Matter Most

These cases are usually record-intensive. Frequently important documents include:

• Prescribing records: Indication, planned duration, and counseling documented in the chart.
• Pharmacy fill history: Dispensing date, directions, quantity, and refill data.
• Early urgent care/ER notes: Often the first objective documentation of rash and mucosal involvement.
• Dermatology consults: Morphology, body surface area estimates, and differential diagnosis.
• Biopsy/pathology (if done): May help distinguish SJS/TEN from mimics, though not every patient has a biopsy.
• Ophthalmology records: Acute involvement and long-term sequelae.
• Inpatient medication administration record: New drugs given in the hospital can become alternative suspects.
• Photos: Patient or clinician photos may help document progression and mucosal involvement.

Common Defense Arguments in Augmentin–SJS Causation Disputes

Common defense themes include:

• Alternative cause: The underlying infection or a virus caused the eruption, not the medication.
• Another drug is more likely: Especially where another medication has a stronger association in the literature or an earlier start date.
• Timing does not fit: Onset is allegedly too early/late or poorly documented.
• Diagnosis is uncertain: Arguing a different condition (for example, erythema multiforme or other drug eruptions) rather than SJS/TEN.
• Methodology problems: Claiming the expert opinion is not reliably tied to the record or accepted reasoning.

Legal Causation in California: Substantial Factor (High-Level)

California civil juries are generally instructed that a cause can be a substantial factor in bringing about harm, even if it is not the only cause. See CACI No. 430 (Causation: Substantial Factor). How that standard applies to a specific case is highly fact-dependent and often driven by expert testimony and the medical record.

FAQ

How soon after starting Augmentin can SJS/TEN appear?

Timing is case-specific and is commonly evaluated against the documented start date, symptom onset, and competing exposures. Your medical records and pharmacy history are typically more important than estimates.

Do you need a biopsy to prove SJS/TEN?

Not always. Some cases are diagnosed clinically, but pathology can be helpful when the diagnosis is disputed or mimics are raised.

What if more than one drug was started?

Multi-drug exposure is common. Experts often address this with a differential etiology that weighs timing, known association strength in the literature, and alternative explanations supported by the record.

Is this medical or legal advice?

No. This is general information for California. Suspected SJS/TEN symptoms can be a medical emergency; seek urgent medical care.

When to Speak With Counsel

Consider speaking with an attorney experienced in pharmaceutical injury matters if SJS/TEN was diagnosed or suspected, symptoms began after starting Augmentin, hospitalization occurred, or there are lasting complications (including ocular injury). A lawyer can help obtain records, coordinate expert review, and evaluate causation and other legal elements.

Call to action: Contact our team to discuss a potential medication injury matter.